The LTEN Board of Directors has elected its newest member, Charlie Kirk of Amgen. Kirk’s term begins immediately.
Kirk is executive director, commercial training and development, rare disease for Amgen. He’s worked in life sciences sales, training and leadership since starting his career at Abbott Laboratories in 1997. He’s also held key leadership positions with AstraZeneca, Salix Pharmaceuticals, Ironwood Pharmaceuticals, TGaS Advisors and Alkermes, before leading the commercial training organization at Horizon Therapeutics in September 2020. Horizon Therapeutics was acquired by Amgen in October 2023.
“I’m excited to take a seat on the LTEN Board of Directors,” Kirk said. “LTEN is an invaluable organization in the life sciences training industry, and it’ll be my honor to help lead, direct and guide programs designed to bring professional value to all of our members and everyone they work with, support and train.”
“Charlie is a perfect addition to the LTEN board and I know he’ll bring immediate value to our network,” said Lauren Harbert, executive director for LTEN. “He’s had strong experience in life sciences on both the industry and supplier sides, and that perspective will help us ensure LTEN meets the needs of all members.”
